Mohammad Alashqar/LinkedIn
May 20, 2026, 12:42
Mohammad Alashqar: Cost-Effectiveness of Fitusiran Prophylaxis in Severe Hemophilia A Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Proud to present poster N 3044 at ISPOR – The Professional Society for Health Economics and Outcomes Research 2026 on the ‘cost-effectiveness of fitusiran prophylaxis versus FVIII prophylaxis or on-demand therapy for patients with severe hemophilia A without inhibitors.’
Grateful to represent The Ohio State University College of Pharmacy and contribute to discussions advancing HEOR, value assessment, and evidence-based care.”
Stay updated with Hemostasis Today.
-
Jul 6, 2026, 13:28Inna Vilshanivska: Sharing Ukraine’s Experience in Blood Donor Retention at the ISBT 2026
-
Jul 6, 2026, 13:10Arun V. J.: Did You Know A Glass Of Water is The Best Way To Retain A Blood Donor?
-
Jul 6, 2026, 13:10Javed Anees: The Hidden Power of Biotin in Modern Medicine
-
Jul 6, 2026, 12:46Saneha Anjum Shaikh: Red Cell Aliquoting – Precision in Transfusion Medicine
-
Jul 6, 2026, 12:43Jennifer Dumont: WFH 2026 Congress Highlights – Expert Insights on Hemophilia Care
-
Jul 6, 2026, 12:39Muhammad Hamza: Can Hemolysis Affect Laboratory Results?
-
Jul 6, 2026, 12:32Syed A. Rizvi: Natural Blood Thinners – What Does the Science Really Say
-
Jul 6, 2026, 12:27Abdul Mannan: Perioperative Bridging of Warfarin Patients Is a Risk-Based Decision
-
Jul 6, 2026, 12:20Wolfgang Miesbach: ISTH 2026 Marks a New Era in Immune Thrombocytopenia Management